Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota

Noa Eliakim –Raz, Jihad Bishara

Research output: Contribution to journalReview articlepeer-review

Abstract

This review summarizes the latest advances in treating and preventing Clostridium difficile infection (CDI), the most common infectious disease cause of nosocomial diarrhea in adults in developed countries. As customary antibiotic therapies against C. difficile, metronidazole and vancomycin, are broad spectrum, they affect greatly the gut microbiota, which result in very high recurrence rates. Therefore, new strategies are researched intensively. New therapies focus on limiting further destruction of the gut microbiota or restoring the microbiota to its pre-destructed state. These include new antibiotics, such as fidaxomicin, which demonstrates reduced CDI recurrences, among other new drugs, biotherapeutic strategies, mainly fecal microbiota transplantation but also competitive inhibition with non-toxigenic strains of C. difficile, and finally, monoclonal antibodies against C. difficile toxins which offer protection against recurrences.

Original languageEnglish
Pages (from-to)1453-1456
Number of pages4
JournalHuman Vaccines and Immunotherapeutics
Volume15
Issue number6
DOIs
StatePublished - 3 Jun 2019

Keywords

  • Clostridium difficile
  • diarrhea
  • microbiota
  • revention
  • treatment

Fingerprint

Dive into the research topics of 'Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota'. Together they form a unique fingerprint.

Cite this